BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · IEX Real-Time Price · USD
1.650
-0.020 (-1.20%)
At close: Jul 19, 2024, 4:00 PM
1.640
-0.010 (-0.61%)
Pre-market: Jul 22, 2024, 7:44 AM EDT
BioRestorative Therapies Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for BRTX stock has a target of 15, which predicts an increase of 809.09% from the current stock price of 1.65.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 12, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for BRTX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +809.09% | Jun 12, 2024 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +809.09% | Aug 14, 2023 |
| Roth Capital | Roth Capital | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +809.09% | Dec 7, 2022 |
| Maxim Group | Maxim Group | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +263.64% | Sep 28, 2022 |
| Roth Capital | Roth Capital | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 1, 2021 |
Financial Forecast
Revenue This Year
573.75K
from 145.80K
Increased by 293.52%
Revenue Next Year
1.21M
from 573.75K
Increased by 110.72%
EPS This Year
-2.23
from -2.47
EPS Next Year
-2.21
from -2.23
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.1M | 2.4M | 3.0M | 94.7M | 194.8M |
| Avg | 573,750 | 1.2M | 1.5M | 47.8M | 96.8M |
| Low | 122,500 | 117,600 | 117,600 | 3.4M | 4.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 620.2% | 311.9% | 144.3% | 6,232.5% | 307.4% |
| Avg | 293.5% | 110.7% | 23.7% | 3,095.7% | 102.4% |
| Low | -16.0% | -79.5% | -90.3% | 130.3% | -91.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.27 | -1.93 | -1.44 | 2.90 | 6.12 |
| Avg | -2.23 | -2.21 | -1.74 | 2.82 | 5.95 |
| Low | -2.17 | -2.45 | -2.01 | 2.70 | 5.71 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 117.4% |
| Avg | - | - | - | - | 111.2% |
| Low | - | - | - | - | 102.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.